Cynosure's revenue per share for the
three
months ended in Dec. 2016 was $5.15.
Cynosure's revenue per share for the trailing twelve months (TTM) ended in Dec. 2016 was $18.34.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Cynosure's Revenue per Share or its related term are showing as below:
CYNO's 3-Year Revenue Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 7.5 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
Cynosure Revenue per Share Historical Data
The historical data trend for Cynosure's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cynosure's Revenue per Share
For the Medical Devices subindustry, Cynosure's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cynosure's PS Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cynosure's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cynosure's PS Ratio falls into.
Cynosure Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Cynosure's Revenue Per Share for the fiscal year that ended in Dec. 2016 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.34
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cynosure (NAS:CYNO) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Cynosure Revenue per Share Related Terms
Thank you for viewing the detailed overview of Cynosure's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Cynosure Inc was incorporated in July 1991. The Company develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. It has also developed an aesthetic treatment product for the home use market. The Company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Australia, Korea, China, Japan and Mexico and through international distributors in approximately 120 other countries. Its product portfolio is composed of various energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. It offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. It offers multiple technologies and system alternatives at various price points depending mainly on the number and type of energy sources included in the system. Its products are designed to be easily upgradeable to add additional energy sources and handpieces, which provide its customers with technological flexibility as it expand their practices. The Company's latest innovations are SmartLipo system and PicoSure system. The Company's flagship products include Elite, Affirm/SmartSkin, Cynergy, Accolade. The Company sells its aesthetic treatment systems to the traditional physician customer base of dermatologists and plastic surgeons as well as to non-traditional physician customers who are providing aesthetic services using laser and light-based technology. Non-traditional physician customers can include primary care physicians, obstetricians and gynecologists. As of December 31, 2013, the Company owns over 60 United States patents, as well as many United States pending applications and foreign patents and pending applications. It is also joint owners with El.En. of certain patents and pending applications. The Company competes with Cutera, Solta Medical, Syneron Medical, ZELTIQ Aesthetics, Alma Lasers among others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, as well as other regulatory bodies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYNO has been successfully added to your 